title: Novel inhibitors of the alphavbeta3 integrin--lead identification strategy.
abstract: A novel approach to inhibition of the alphavbeta3 integrin is described, which uses compounds designed to generate nM potency without using the arginine binding site.
authors: AstraZeneca, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
authors: David
authors: D
authors: Elliot
authors: Eleanor
authors: E
authors: Henshaw
authors: Philip A
authors: PA
authors: MacFaul
authors: Andrew D
authors: AD
authors: Morley
authors: Peter
authors: P
authors: Newham
authors: Keith
authors: K
authors: Oldham
authors: Ken
authors: K
authors: Page
authors: Neil
authors: N
authors: Rankine
authors: Paul
authors: P
authors: Sharpe
authors: Attilla
authors: A
authors: Ting
authors: Christine M
authors: CM
authors: Wood
mesh_terms: D000818:Animals; D001665:Binding Sites; D003198:Computer Simulation; D015195:Drug Design; D006801:Humans; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D009842:Oligopeptides / Q000737:chemistry; D051381:Rats; D054852:Small Molecule Libraries; D013329:Structure-Activity Relationship
chemical_list: D039302:Integrin alphaVbeta3; D009842:Oligopeptides; D054852:Small Molecule Libraries; C047981:arginyl-glycyl-aspartic acid